RECEIVED
CENTRAL FAX CENTER
MAR 10 2005

FAX TRANSMISSION

DATE: March 10, 2005

PTO IDENTIFIER: **Application Number** 09/891,865
Patent Number

Inventor: Giuseppina Bestetti et al.

MESSAGE TO: Examiner David J. Steadman, Ph.D.
US Patent and Trademark Office

FAX NUMBER: (703) 872-9306

FROM: DARBY & DARBY P.C.
Heather Morehouse Ettinger, Ph.D.

PHONE: (212) 836-3744

Attorney Dkt. #: 02901/000J410-US0

PAGES (Including Cover Sheet): 4

CONTENTS:

Certificate of Transmission (1 page)
Proposed Claims (2 pages)

Attached please find claims for an After-Allowance Amendment under 37 C.F.R. § 1.312 for U.S.S.N. 09/891,865. Pursuant to a telephone call on March 9, 2005 from Examiner Steadman to Applicants' representative Heather Ettinger, the claims filed with the After-Allowance Amendment filed on Jan. 21, 2005 have been amended. Specifically, the claims have been renumbered and claim 76 has been amended to end with the phrase "wherein the proteins are produced," so as to make the end of the claim consistent with the preamble of the claim. Please contact me if you have any questions. The claims submitted herewith differ from those submitted on March 9, only by presenting the proper status identifier of each claim.

DARBY & DARBY P.C.
P.O. Box 5257, New York, New York 10150-5257
Telephone: (212) 527-7700 **Facsimile:** (212) 527-7701

Heather Morehouse Ettinger
Registration No. 51,658

RECEIVED
CENTRAL FAX CENTER

MAR 10 2005

PTO/SB/97 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (If known): 09/891,865 Attorney Docket No.: 02901/000J410-US0

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on March 10, 2005
Date

Signature

Anne Arlouskas
Typed or printed name of person signing Certificate

Registration Number, if applicable

(212) 836-3741
Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Fax Transmission (1 page)
Proposed Claims (2 pages)

Claims for After-Allowance Amendment under 37 C.F.R. § 1.312 for U.S.S.N. 09/891,865

1-42. (Cancelled)

43. (Previously Presented) A plasmid vector having the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.

44-75. (Cancelled)

76. (New) A method for producing a first protein having uridine phosphorylase activity and a second protein having purine nucleoside phosphorylase activity in the same cell, said method comprising culturing a host bacterial cell harboring a plasmid expression vector having the sequence as depicted in SEQ ID NO: 6 or a plasmid expression vector having the sequence as depicted in SEQ ID NO: 15, wherein the proteins are produced.

77. (New) The method of claim 76, further comprising the steps of isolating and purifying the proteins from the host bacterial cell.

78. (New) A method for producing a fusion protein having both uridine phosphorylase activity and purine nucleoside phosphorylase activity, said method comprising culturing a host bacterial cell harboring a plasmid expression vector having the sequence as depicted in SEQ ID NO: 9, wherein the protein is produced.

79. (New) The method of claim 78, further comprising the steps of isolating and purifying the protein from the host bacterial cell.

80. (New) A method for producing a fusion protein having both uridine phosphorylase activity and purine nucleoside phosphorylase activity, said method comprising culturing a host bacterial cell harboring a plasmid expression vector having the sequence as depicted in SEQ ID NO: 10, wherein the protein is produced.

81. (New) The method of claim 80, further comprising the steps of isolating and purifying the fusion protein from the host bacterial cell.